WO2009056232A2 - Combination of pde5 inhibitors with muscarinic receptor antagonists - Google Patents
Combination of pde5 inhibitors with muscarinic receptor antagonists Download PDFInfo
- Publication number
- WO2009056232A2 WO2009056232A2 PCT/EP2008/008765 EP2008008765W WO2009056232A2 WO 2009056232 A2 WO2009056232 A2 WO 2009056232A2 EP 2008008765 W EP2008008765 W EP 2008008765W WO 2009056232 A2 WO2009056232 A2 WO 2009056232A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bladder
- beta
- muscarinic receptor
- renal
- combination
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title claims abstract description 21
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title claims description 29
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title claims description 29
- 206010071289 Lower urinary tract symptoms Diseases 0.000 claims description 18
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims description 16
- 239000003149 muscarinic antagonist Substances 0.000 claims description 15
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 14
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 229960002381 vardenafil Drugs 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000000018 receptor agonist Substances 0.000 claims description 10
- 229940044601 receptor agonist Drugs 0.000 claims description 10
- 208000017169 kidney disease Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 206010071445 Bladder outlet obstruction Diseases 0.000 claims description 6
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 6
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 claims description 6
- 206010046543 Urinary incontinence Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 6
- OTNWKGOOTUSAND-UHFFFAOYSA-N 3-(3,4-dihydro-2h-chromen-2-ylmethylamino)propane-1,2-diol Chemical compound C1=CC=C2OC(CNCC(O)CO)CCC2=C1 OTNWKGOOTUSAND-UHFFFAOYSA-N 0.000 claims description 5
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 208000020629 overactive bladder Diseases 0.000 claims description 5
- -1 Tadalafϊl Chemical compound 0.000 claims description 4
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- 206010029155 Nephropathy toxic Diseases 0.000 claims description 3
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims description 3
- 206010029279 Neurogenic bladder Diseases 0.000 claims description 3
- 208000036576 Obstructive uropathy Diseases 0.000 claims description 3
- 208000000450 Pelvic Pain Diseases 0.000 claims description 3
- 208000033626 Renal failure acute Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 201000011040 acute kidney failure Diseases 0.000 claims description 3
- 208000012998 acute renal failure Diseases 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 208000035474 group of disease Diseases 0.000 claims description 3
- 201000001881 impotence Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 231100000417 nephrotoxicity Toxicity 0.000 claims description 3
- 208000024449 overflow incontinence Diseases 0.000 claims description 3
- 229960003310 sildenafil Drugs 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 206010046494 urge incontinence Diseases 0.000 claims description 3
- 208000014001 urinary system disease Diseases 0.000 claims description 3
- 201000002327 urinary tract obstruction Diseases 0.000 claims description 3
- 210000002229 urogenital system Anatomy 0.000 claims description 3
- ZGGNJJJYUVRADP-ACJLOTCBSA-N 2-[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(Cl)C=CC=1)C1=CC=C(OCC(O)=O)C=C1 ZGGNJJJYUVRADP-ACJLOTCBSA-N 0.000 claims description 2
- VMMYRRFPMAGXNP-BTYIYWSLSA-N 2-[4-[2-[[(1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]-2,5-dimethylphenoxy]acetic acid Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC(C)=C(OCC(O)=O)C=C1C VMMYRRFPMAGXNP-BTYIYWSLSA-N 0.000 claims description 2
- RCJYGWGQCPDYSL-HZPDHXFCSA-N 7-[(3-bromo-4-methoxyphenyl)methyl]-1-ethyl-8-[[(1r,2r)-2-hydroxycyclopentyl]amino]-3-(2-hydroxyethyl)purine-2,6-dione Chemical compound C=1C=C(OC)C(Br)=CC=1CN1C=2C(=O)N(CC)C(=O)N(CCO)C=2N=C1N[C@@H]1CCC[C@H]1O RCJYGWGQCPDYSL-HZPDHXFCSA-N 0.000 claims description 2
- 206010053236 Mixed incontinence Diseases 0.000 claims description 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 2
- 229960000307 avanafil Drugs 0.000 claims description 2
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 claims description 2
- 229960002677 darifenacin Drugs 0.000 claims description 2
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims description 2
- 229950003418 dasantafil Drugs 0.000 claims description 2
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 claims description 2
- 229950008844 ritobegron Drugs 0.000 claims description 2
- LLDXOPKUNJTIRF-QFIPXVFZSA-N solabegron Chemical compound C([C@H](O)C=1C=C(Cl)C=CC=1)NCCNC(C=1)=CC=CC=1C1=CC=CC(C(O)=O)=C1 LLDXOPKUNJTIRF-QFIPXVFZSA-N 0.000 claims description 2
- 229950009659 solabegron Drugs 0.000 claims description 2
- 229960003855 solifenacin Drugs 0.000 claims description 2
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims description 2
- 208000022170 stress incontinence Diseases 0.000 claims description 2
- 229960001491 trospium Drugs 0.000 claims description 2
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 claims description 2
- 229960000438 udenafil Drugs 0.000 claims description 2
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract description 9
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract description 9
- 239000003112 inhibitor Substances 0.000 abstract description 7
- 102000012740 beta Adrenergic Receptors Human genes 0.000 abstract description 4
- 108010079452 beta Adrenergic Receptors Proteins 0.000 abstract description 4
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract description 2
- 239000000556 agonist Substances 0.000 description 18
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 17
- 101150098694 PDE5A gene Proteins 0.000 description 17
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 9
- 230000008602 contraction Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001022 anti-muscarinic effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- 206010021639 Incontinence Diseases 0.000 description 3
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 description 3
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 3
- 229940095074 cyclic amp Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 206010029446 nocturia Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000005068 bladder tissue Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000036316 preload Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 229960000835 tadalafil Drugs 0.000 description 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 2
- 229960004045 tolterodine Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000017934 GABA-B receptor Human genes 0.000 description 1
- 108060003377 GABA-B receptor Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229940126083 M3 antagonist Drugs 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000002003 Neurokinin-3 Receptors Human genes 0.000 description 1
- 108010040716 Neurokinin-3 Receptors Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 102000042565 transient receptor (TC 1.A.4) family Human genes 0.000 description 1
- 108091053409 transient receptor (TC 1.A.4) family Proteins 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Definitions
- the present invention relates to combinations of phosphodiesterases (PDEs) and muscarinic receptors and the pharmacology of PDE inhibitors and muscarinic receptor antagonists. More particularly, the invention is related to combinations of PDE5 inhibitors and muscarinic receptor antagonists.
- PDEs phosphodiesterases
- the present invention relates further to combinations of phosphodiesterases (PDEs) and beta adrenergic receptors and the pharmacology of the combinations of PDE inhibitors and beta adrenergic receptor agonists. More particularly, the invention is related to combinations of PDE5 inhibitors and beta-3 adrenergic receptor agonists.
- PDEs phosphodiesterases
- beta adrenergic receptor agonists More particularly, the invention is related to combinations of PDE5 inhibitors and beta-3 adrenergic receptor agonists.
- OAB Ovaractive Bladder
- UUI Urge Urinary Incontinence
- BTX Botulinustoxin
- RTX Resiniferatoxin
- the main treatment option is based on muscarinergic-receptor antagonists (antimuscarinics).
- Antimuscarinics prevent acetylcholine- induced contraction of the detrusor muscle during filling phase mainly by blocking postsynaptic M- 3 receptors on the bladder smooth muscle (Wang 1995, Andersson 2004).
- efficacy of these drugs is limited, they show a slow onset of action and cause adverse effects such as dry mouth or constipation (Herbison 2003, Chappie 2005).
- Phosphodiesterase PDEs
- PDE-5 Phosphodiesterase
- cAMP production in the bladder can be stimulated by agonists of the GS-coupled beta3 adrenergic receptor, which is the predominant beta adrenergic receptor on the bladder smooth muscle cells. It has now been found, that the elevation of the cGMP level via PDE5 inhibitor-treatment and the blocking of the Muscarinic Recpetor results in unexpected and significant higher efficacy, compared to each single treatment, if combinations of PDE5 inhibitors and beta3 agonists are used in the treatment and that the elevation of the cGMP level and cAMP level results in unexpected and significant higher efficacy, compared to each single treatment, if combinations of PDE5 inhbitors and beta3 agonists are used in the treatment.
- PDE5 are for example inhibitors selected from the group of PDE5 inhibitors consisting of, Sildenafil, Tadalafil, Udenafil, Dasantafil, Avanafil, SLx2101 and LAS34179 whereas Vardenafil is the preferred PDE5 inhibitor.
- Muscarinic Receptor antagonists according to the invention are for example inhibitors selected from the group of Muscarinic Receptor Antagonists consisting of, Oxybutinine, Trospium, Tolterodin, Solifenacin, Fesoterodin and Darifenacin.
- Beta 3 receptor agonists according to the invention are for example agonists selected from the group consisting of BRL-37344, Cl-316234, YM-178, Solabegron, and Ritobegron whereas 2- ((2,3-Dihydroxypropyl)Aminomethyl)chroman derivates are preferred beta 3 receptor agonists.
- PDE5 inhibitors muscarinic receptor antagonists and beta 3 receptor agonists are known in the art.
- the PDE5 inhibitors and muscarinic receptor antagonists can be combined in the dose range of 1 to 20mg once daily of the PDE5 inhibitor and 1 to 15mg once daily of the muscarinic receptor antagonist.
- the PDE5 inhibitors and beta 3 receptor agonists can be combined in the dose range of 1 to 20mg once daily of the PDE5 inhibitor and 0.1 to lOmg once daily of the beta3 agonist.
- the combinations according to the invention can be used for the preparation of medicaments for the treatment of a disease comprised in a group of diseases consisting of Benign Prostate Hyperplasia (BPH), Bladder Outlet Obstruction (BOO), Lower Urinary Tract Symptoms (LUTS), genitourinary disorders comprising neurogenic bladder syndrome (overactive bladder - OAB, Interstitial Cystits - IC), urinary incontinence (UI) like mixed-, urge, stress- or overflow incontinence (MUI; UUI, SUI, OUI), pelvic pain.
- BPH Benign Prostate Hyperplasia
- BOO Bladder Outlet Obstruction
- LUTS Lower Urinary Tract Symptoms
- genitourinary disorders comprising neurogenic bladder syndrome (overactive bladder
- the combinations according to the invention can further be used for the preparation of medicaments for the treatment of other urological disorders and in particular and with substantial advantage in the treatment of benign and malign disorders of the organs consisting the genitourinary system of female and male, renal diseases like acute or chronic renal failure, immunologically mediated renal disease like renal transplant rejection, lupus nephritis, immune complex renal disease, glomerulaopathies, nephritis, toxic nephropathy, obstructive uropathies and erectile dysfunction.
- Tissue preparation Wistar Rats (200-25Og) are euthanized due to the German Law for the protection of laboratory animals.
- Bladder tissue is removed and placed in ice-cold Krebs-Henseleit buffer of following composition (in mmol/1): NaCl 112, KCl 5.9, CaCl 2 2.0 MgCl 2 1.2, NaH 2 PO 4 1.2, NaHCO 3 25, glucose 11.5.
- KCl 5.9 CaCl 2 2.0 MgCl 2 1.2, NaH 2 PO 4 1.2, NaHCO 3 25, glucose 11.5.
- Four equally sized longitudinal strips of approximately 2 mm x 10 mm are cut from the bladder body.
- each experiment is started by exposing the preparation to K + (50 mmol/1) Krebs-Henseleit solution. The procedure is repeated 3 times and the tissues are washed at least tree times between each contraction. The bladder strips are than pre-contracted using K + (50 mmol/1) Krebs-Henseleit solution.
- K + 50 mmol/1) Krebs-Henseleit solution
- an accumulative dose response curve of the compound tested is constructed.
- the stabilized contraction induced by K + (50 mmol/1) Krebs-Henseleit solution is defined as 100% tension.
- the relaxation is expressed as percentage tension.
- Tissue sampling and RNA preparation Male (m) and Female (fin) Sprague Dawley rats with a body weight between 200-250 g are used for tissue collecting.
- the rats are briefly anaesthetized with a mixture of 5% Isoflurane (Baxter S.A.) in a carrier with 70% N 2 O and 30% O 2 , and than euthanized by decapitation.
- the abdomen is opened by a midline incision and the bladder is quickly removed.
- the bladder is dissected in the bladder neck, referred as bladder Trigone (T) and bladder detrusor muscle (DM).
- T bladder Trigone
- DM bladder detrusor muscle
- the tissues are frozen in liquid N2 and stored until RNA preparation.
- Total RNA is isolated using RNeasy mini columns (Qiagen Inc.) and further purified by DNase digestion.
- PDE5 and beta3 adrenergic Receptor (beta3 AR) mRNA quantification The mRNA expression of the PDE5 and beta3 AR in the male and female rat bladder trigone (termed m-T and fm-T) and rat baldder detrusor muscle (termed m-DM and fin-DM) is measured by real time quantitative PCR (TaqMan-PCR, Heid 1996). Therefore 1 ⁇ g of total RNA are transcribed into cDNA with Superscript II RT cDNA synthesis kit (Gibco, Inc) according to the manual of the supplier.
- Superscript II RT cDNA synthesis kit Gibco, Inc
- the mRNA for the PDEs is measured by real-time quantitative RT-PCR on an ABI Prism 7700 sequence detection instrument (Applied Biosystems, Inc.). Specific Sequences for forward and reverse primers as for the fluorogenic probe of PDE5 and beta3 AR mRNA are designed by Primer Express 1.5 Software (Applied Biosystems, Inc.).
- 5' nucleolytic activity of Taq polymerase cleaves the probe separating the 5' reporter fluorescent dye from the 3' quencher dye.
- the threshold cycle, Ct which correlates inversely with the target mRNA level, is measured as the cycle number at which the reporter fluorescent emission increases 10 standard deviations above background level.
- beta-action is quantified as described above, using as forward primer 5'-accttcaacaccccagcca-3', reverse primer 5'- cagtggtacgaccagaggca-3 ' and fluorescent probe 5'-6AFM-acgtagccatccaggctgtgttgtcc-TAMARA- 3'.
- the mRNA levels are corrected for beta-actin mRNA levels and calculated as relative expression using comparative Ct-method.
- inhibitors of PDE-5 or agonists of beta3 AR include inhibitors of PDE-5 or agonists of beta3 AR, but in particular combinations of both, PDE5 inhibitors and beta3 AR agonists, such as Vardenaf ⁇ l in combination with beta3 AR agonists, such as 2-((2,3-Dihydroxypropyl)Aminomethyl)chroman derivates reduce bladder tone synergistically.
- Tissue preparation Male Beagle dogs (15-16kg) are euthanized due to the German Law for the protection of laboratory animals. Bladder tissue is removed and placed in ice-cold Krebs-Henseleit buffer of following composition (in mmol/1): NaCl 112, KCl 5.9, CaCl 2 2.0 MgCl 2 1.2, NaH 2 PO 4 1.2, NaHCO 3 25, glucose 11.5. Four equally sized longitudinal strips of approximately 2 mm x 10 mm are cut from the bladder body.
- each experiment is started by exposing the preparation to K + (50 mmol/1) Krebs-Henseleit solution. The procedure is repeated 3 times and the tissues are washed at least tree times between each contraction. The bladder strips are than pre-contracted using K + (50 mmol/1) Krebs-Henseleit solution.
- K + 50 mmol/1) Krebs-Henseleit solution
- an accumulative dose response curve of the compound tested is constructed.
- the stabilized contraction induced by K + (50 mmol/1) Krebs-Henseleit solution is defined as 100% tension.
- the relaxation is expressed as percentage tension.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to combinations of phosphodiesterases (PDEs) and muscarinic receptors or beta adrenergic receptors and the pharmacology of PDE inhibitors and muscarinic receptor antagonists or beta adrenergic receptors.
Description
Combination of PDE5 inhibitors with Muscarinic Receptor antagonists
Technical field of the invention
The present invention relates to combinations of phosphodiesterases (PDEs) and muscarinic receptors and the pharmacology of PDE inhibitors and muscarinic receptor antagonists. More particularly, the invention is related to combinations of PDE5 inhibitors and muscarinic receptor antagonists.
The present invention relates further to combinations of phosphodiesterases (PDEs) and beta adrenergic receptors and the pharmacology of the combinations of PDE inhibitors and beta adrenergic receptor agonists. More particularly, the invention is related to combinations of PDE5 inhibitors and beta-3 adrenergic receptor agonists.
Background of the invention
Ovaractive Bladder (OAB) is a term, defined by the International Continence Society (Abrams 2002), and is a symptomatic diagnosis. OAB is usually defined as urgency with or without incontinence, frequency and nocturia. Urgency is often described as sudden and compelling desire to pass urine which could be accompanied by the involuntary leakage of urine (UUI). In addition patients display higher frequency with more then 8 voidings during day-time and nocturia, with more then 1 voiding during sleeping-time. Urge Urinary Incontinence (UUI) is the most bothersome symptom of OAB and is associated with a significantly reduced quality of life of the patients (Jackson 1997).
The overall prevalence in OAB in Western Europe is 16 and 17% in men and women, respectively, with similar finding in the US and an increase of the incidence with age (Milsom 2001, Stewart 2003). The pathophysiology of this disease is not fully understood and seemed to be multi-factorial. The voiding process is tightly regulated by neural circuits in the brain and the spinal cord, coordinating the activity of the smooth muscle in bladder and urethra. Thus, various neurological disorders and aging unbalance this well regulated interplay resulting in detrusor overaytivity (DO) (Andersson 2004). Moreover urge incontinence may be due to intrinsic detrusor myogenic abnormalities like spontaneous phasic activity and detrusor instability (Kumar 2005).
Besides local application of Botulinustoxin (BTX) or Resiniferatoxin (RTX) by direct jnjection in the bladder or instillation (Sahai 2006; Patterson 2006), the main treatment option is based on muscarinergic-receptor antagonists (antimuscarinics). Antimuscarinics prevent acetylcholine- induced contraction of the detrusor muscle during filling phase mainly by blocking postsynaptic M- 3 receptors on the bladder smooth muscle (Wang 1995, Andersson 2004). However efficacy of
these drugs is limited, they show a slow onset of action and cause adverse effects such as dry mouth or constipation (Herbison 2003, Chappie 2005). Due to this reasons the compliance of these drugs is low and there are intense efforts to discover and develop new treatment options of OAB and UUI. A broad variety of drugs acting on different targets, i.e. Purinergic Receptors, NK-3 receptors, beta-3 receptors, TRP-channels, K+ channels, GABA-b receptors, Serotonin receptors, were tested which are currently under preclinical and early clinical evaluation within this indication (Yoshimura 2002). The hints that Phosphodiesterase (PDEs), especially PDE-5, could be used for the treatment of OAB and UUI are rare and only indirect. It has been shown that PDE-5 inhibitors reduced the tonus of the bladder muscle (Ueckert 2001, Tinel 2006) and reduced the Lower Urinary Tract Symptoms (LUTS) in rats in vivo (Tinel 2006). This was paralleled by findings in BPH patients which reported significant reduction of LUTS after treatment with Sildenafil (McVary 2006; Kaplan 2006; Mulhall 2006) and Tadalafil (Roehrborn 2006) and Vardenafil (Neuser, personal communication). Since LUTS comprise urgency, frequency and nocturia LUTS in BPH patients is similar to UUI in OAB patients (Chappie 2006). Both, LUTS and UUI symptoms are originated within the bladder and characterized by Detrusor Overactivity (Chappie 2006). This could explain why the M-3 antagonist tolterodine which is normally used in OAB patients, if used in BPH patients with LUTS, significantly improved the symptoms (Lee 2004, Kaplan 2006). Thus, one might assume if PDE-5 inhibition which reduced LUTS in BPH patients might be able to reduce UUI symptoms in OAB patients. This is further supported since both, PDE-5 inhibitors and antimuscarinics target the bladder muscle, reducing the bladder tone (Ueckert 2001, Tinel 2006) and therefore - at least in part - could decrease detrusor overactivity. In addition, dilatation of the bladder by cGMP) allows prolonged and smoother filling of the bladder, which might increase bladder capacity and result in reduction of the micturition frequency after PDE-5 inhibition. Our experiments now showed that combination of the cGMP elevation with PDE5 in combination with the well established standard theraphy with Antimuscarinics resulted in unexpected and significant higher efficacy of the combination of PDE5 inhbitors and Antimuscarinics, when compared to each single treatment.
Our experiments using distinct preclinical in vitro and in vivo model now showed that PDE5 inhibition in combination with Muscarinic Receptor antagonists is a very effective treatment for detrusor overacitvity, overactive bladder (OAB), different forms of incontinence i.e. urge urinary incontinence (UUI); and also of Lower Urinary Tract Symptoms (LUTS) and symptoms associated with Benign Prostate Hyperplasia (BPH). Combinations of PDE5 inhibition with beta3 activation resulted in increased efficacy in vitro and in vivo. In addition cyclic AMP (cAMP) plays an important role in regulating smooth muscle tone. cAMP production in the bladder can be stimulated by agonists of the GS-coupled beta3 adrenergic receptor, which is the predominant beta adrenergic receptor on the bladder smooth muscle cells.
It has now been found, that the elevation of the cGMP level via PDE5 inhibitor-treatment and the blocking of the Muscarinic Recpetor results in unexpected and significant higher efficacy, compared to each single treatment, if combinations of PDE5 inhibitors and beta3 agonists are used in the treatment and that the elevation of the cGMP level and cAMP level results in unexpected and significant higher efficacy, compared to each single treatment, if combinations of PDE5 inhbitors and beta3 agonists are used in the treatment.
It has further been found that combinations of PDE5 inhibitiors with beta3 agonists are very effective for the treatment of detrusor overacitvity, overactive bladder (OAB), different forms of incontinence i.e. urge urinary incontinence (UUI); and also of Lower Urinary Tract Symptoms (LUTS) and symptoms associated with Benign Prostate Hyperplasia (BPH). Those combinations of PDE5 inhibitiors with beta3 agonists resulted in over-additively increased efficacy in vitro and in vivo tests. Therefore this combination will extend the treatment options of the aforementioned diseases significantly. Thus the mRNA expression of PDE-5 and beta-3 in the bladder and in the lower urinary tract is nearly semi-quantitated using the combinations according to the invention.
PDE5 according to the invention are for example inhibitors selected from the group of PDE5 inhibitors consisting of, Sildenafil, Tadalafil, Udenafil, Dasantafil, Avanafil, SLx2101 and LAS34179 whereas Vardenafil is the preferred PDE5 inhibitor.
Muscarinic Receptor antagonists according to the invention are for example inhibitors selected from the group of Muscarinic Receptor Antagonists consisting of, Oxybutinine, Trospium, Tolterodin, Solifenacin, Fesoterodin and Darifenacin.
Beta 3 receptor agonists according to the invention are for example agonists selected from the group consisting of BRL-37344, Cl-316234, YM-178, Solabegron, and Ritobegron whereas 2- ((2,3-Dihydroxypropyl)Aminomethyl)chroman derivates are preferred beta 3 receptor agonists.
These PDE5 inhibitors, muscarinic receptor antagonists and beta 3 receptor agonists are known in the art.
The PDE5 inhibitors and muscarinic receptor antagonists can be combined in the dose range of 1 to 20mg once daily of the PDE5 inhibitor and 1 to 15mg once daily of the muscarinic receptor antagonist.
The PDE5 inhibitors and beta 3 receptor agonists can be combined in the dose range of 1 to 20mg once daily of the PDE5 inhibitor and 0.1 to lOmg once daily of the beta3 agonist.
The combinations according to the invention can be used for the preparation of medicaments for the treatment of a disease comprised in a group of diseases consisting of Benign Prostate Hyperplasia (BPH), Bladder Outlet Obstruction (BOO), Lower Urinary Tract Symptoms (LUTS), genitourinary disorders comprising neurogenic bladder syndrome (overactive bladder - OAB, Interstitial Cystits - IC), urinary incontinence (UI) like mixed-, urge, stress- or overflow incontinence (MUI; UUI, SUI, OUI), pelvic pain.
The combinations according to the invention can further be used for the preparation of medicaments for the treatment of other urological disorders and in particular and with substantial advantage in the treatment of benign and malign disorders of the organs consisting the genitourinary system of female and male, renal diseases like acute or chronic renal failure, immunologically mediated renal disease like renal transplant rejection, lupus nephritis, immune complex renal disease, glomerulaopathies, nephritis, toxic nephropathy, obstructive uropathies and erectile dysfunction.
Examples
Example 1
Tissue preparation: Wistar Rats (200-25Og) are euthanized due to the German Law for the protection of laboratory animals. Bladder tissue is removed and placed in ice-cold Krebs-Henseleit buffer of following composition (in mmol/1): NaCl 112, KCl 5.9, CaCl2 2.0 MgCl2 1.2, NaH2PO4 1.2, NaHCO3 25, glucose 11.5. Four equally sized longitudinal strips of approximately 2 mm x 10 mm are cut from the bladder body.
Recording of mechanical activity in the bladder strip assay: The preparations are transferred to 20 ml organ baths containing Krebs-Henseleit solution equilibrated with 95% O2, 5% CO2 at 37°C. The strips are mounted between two hooks by means of two clips. For recording of isometric tension one of the hooks is connected to a force transducer which is in turn linked to an amplifier and chart recorder. The other hook is attached to a movable unit, permitting precise adjustment of preload tension. All tissues are then given a 60 min equilibration period during which they are washed and the resting tension is adjusted to 1 g every 20 min. After the equilibration period, each experiment is started by exposing the preparation to K+ (50 mmol/1) Krebs-Henseleit solution. The procedure is repeated 3 times and the tissues are washed at least tree times between each contraction. The bladder strips are than pre-contracted using K+ (50 mmol/1) Krebs-Henseleit solution. When the contraction is stabilized, an accumulative dose response curve of the compound tested is constructed. The stabilized contraction induced by K+ (50 mmol/1) Krebs-Henseleit solution is defined as 100% tension. The relaxation is expressed as percentage tension.
Results: The effects of a PDE5 inhibitor, i.e. Vardenafil, a muscarinic receptor antagonist, i.e. Toldterodin are tested on isolated and pre-contracted rat bladder strips as described above. Vardenafil at lOμM and the muscarinic receptor antagonist at lOμM relaxed the rat bladder by 82+5% and by 61+3 % respectively. In contrast the combination of Vardenafil at lOμM and the muscarinic receptor antagonist at lOμM led to a significant and enhanced relaxation by 98+3% of the rat bladder strip (Figure 1) completely reversing the pre-contraction of the bladder strip. These results show that combinations of PDE5 inhibitors, i.e. Vardenafil and muscarinic receptor antagonists i.e. Tolterodine acted on the bladder and are superior to mono-therapy.
Example 2
Tissue sampling and RNA preparation: Male (m) and Female (fin) Sprague Dawley rats with a body weight between 200-250 g are used for tissue collecting. The rats are briefly anaesthetized with a mixture of 5% Isoflurane (Baxter S.A.) in a carrier with 70% N2O and 30% O2, and than euthanized by decapitation. The abdomen is opened by a midline incision and the bladder is quickly removed. The bladder is dissected in the bladder neck, referred as bladder Trigone (T) and bladder detrusor muscle (DM). The tissues are frozen in liquid N2 and stored until RNA preparation. Total RNA is isolated using RNeasy mini columns (Qiagen Inc.) and further purified by DNase digestion.
PDE5 and beta3 adrenergic Receptor (beta3 AR) mRNA quantification: The mRNA expression of the PDE5 and beta3 AR in the male and female rat bladder trigone (termed m-T and fm-T) and rat baldder detrusor muscle (termed m-DM and fin-DM) is measured by real time quantitative PCR (TaqMan-PCR, Heid 1996). Therefore 1 μg of total RNA are transcribed into cDNA with Superscript II RT cDNA synthesis kit (Gibco, Inc) according to the manual of the supplier. The mRNA for the PDEs is measured by real-time quantitative RT-PCR on an ABI Prism 7700 sequence detection instrument (Applied Biosystems, Inc.). Specific Sequences for forward and reverse primers as for the fluorogenic probe of PDE5 and beta3 AR mRNA are designed by Primer Express 1.5 Software (Applied Biosystems, Inc.). During PCR amplification, 5' nucleolytic activity of Taq polymerase cleaves the probe separating the 5' reporter fluorescent dye from the 3' quencher dye. The threshold cycle, Ct, which correlates inversely with the target mRNA level, is measured as the cycle number at which the reporter fluorescent emission increases 10 standard deviations above background level. As housekeeping gene, beta-action is quantified as described above, using as forward primer 5'-accttcaacaccccagcca-3', reverse primer 5'- cagtggtacgaccagaggca-3 ' and fluorescent probe 5'-6AFM-acgtagccatccaggctgtgttgtcc-TAMARA- 3'. The mRNA levels are corrected for beta-actin mRNA levels and calculated as relative expression using comparative Ct-method.
Results: The results showed that there is substantial PDE-5 mRNA (Figure 2) and beta3 AR mRNA (Figure 3) expression in the bladder, hi addition no gender differences between male and female in either PDE5 or beta 3AR mRNA can be detected. Finally the detrusor muscle and the trigone mRNA expression of PDE5 and beta3 AR is not significant different in this two regions of the bladder. (Figure 2, Figure 3). The expression profile demonstrates that PDE5 and beta3 AR mRNAs are abundant in the bladder, therefore inhibitors of PDE5 and beta3 agonists could act on the bladder tone. Moreover treatment with PDE5 inhibitors and beta3 agonists are efficacious in both genders to a similar extent since no differences of PDE5 or beta3 mRNA in males and females can be detected. Since the mRNA expression of beta3 mRNA and PDE5 is not significant different
in trigone and detrusor muscle a pronounced efficacy of both, PDE5 inhibitors and beta3 agonists can be expected. Thus, inhibitors of PDE-5 or agonists of beta3 AR, but in particular combinations of both, PDE5 inhibitors and beta3 AR agonists, such as Vardenafϊl in combination with beta3 AR agonists, such as 2-((2,3-Dihydroxypropyl)Aminomethyl)chroman derivates reduce bladder tone synergistically.
Example 3
Tissue preparation: Male Beagle dogs (15-16kg) are euthanized due to the German Law for the protection of laboratory animals. Bladder tissue is removed and placed in ice-cold Krebs-Henseleit buffer of following composition (in mmol/1): NaCl 112, KCl 5.9, CaCl2 2.0 MgCl2 1.2, NaH2PO4 1.2, NaHCO3 25, glucose 11.5. Four equally sized longitudinal strips of approximately 2 mm x 10 mm are cut from the bladder body.
Recordine of mechanical activity in the bladder strip assay: The preparations are transferred to 20 ml organ baths containing Krebs-Henseleit solution equilibrated with 95% O2, 5% CO2 at 37°C. The strips are mounted between two hooks by means of two clips. For recording of isometric tension one of the hooks is connected to a force transducer which is in turn linked to an amplifier and chart recorder. The other hook is attached to a movable unit, permitting precise adjustment of preload tension. All tissues are then given a 60 min equilibration period during which they are washed and the resting tension is adjusted to 1 g every 20 min. After the equilibration period, each experiment is started by exposing the preparation to K+ (50 mmol/1) Krebs-Henseleit solution. The procedure is repeated 3 times and the tissues are washed at least tree times between each contraction. The bladder strips are than pre-contracted using K+ (50 mmol/1) Krebs-Henseleit solution. When the contraction is stabilized, an accumulative dose response curve of the compound tested is constructed. The stabilized contraction induced by K+ (50 mmol/1) Krebs-Henseleit solution is defined as 100% tension. The relaxation is expressed as percentage tension.
Results: The effects of a PDE5 inhibitor, i.e. Vardenafil, a beta3 AR agonist, i.e. a 2-((2,3- Dihydroxypropyl)Aminomethyl)chroman derivate and combinations thereof (PDE5 inhibitor, i.e. Vardenafil + beta3 agonist i.e. a derivate of 2-((2,3-Dihydroxypropyl)Arninomethyl)chroman) are tested on isolated and pre-contracted dog bladder strips as described above. Vardenafil at lμM and the beta 3 agonist at lμM relaxed the dog bladder by 29+1% and by 34+2% respectively. In contrast the combination of Vardenafil at lμM and the beta3 AR agonist at lμM led to a significant and enhanced relaxation by 46+3% of the dog bladder strip (Table 1). These results show that combinations of PDE5 inhibitors, i.e. Vardenafil and beta3 AR agonists i.e. 2-((2,3- Dihydroxypropyl)Aminomethyl)chroman derivates acted on the bladder and are superior to monotherapy.
Claims
1. A pharmaceutical composition containing at least one PDE5 inhibitor and at least one muscarinic receptor antagonist or at least one beta 3 receptor agonists.
2. A pharmaceutical composition according to claim 1 containing a PDE5 inhibitor selected from the group consisting of Vardenafil, Sildenafil, Tadalafϊl, Udenafil, Dasantafil, Avanafil, SLx2101 and LAS34179.
3. A pharmaceutical composition according to claim 1 containing a muscarinic receptor antagonist selected from the group consisting of Oxybutinin, Trospium, Tolterodin, Solifenacin, Fesoterodin and Darifenacin.
4. A pharmaceutical composition according to claim 1 containing a beta 3 receptor agonists selected from the group consisting of consisting of BRL-37344, Cl-316234, YM-178, 2- ((2,3-Dihydroxypropyl)Aminomethyl)chroman derivates, Solabegron and Ritobegron.
5. Use of a combination of at least one PDE5 inhibitor and at least one muscarinic receptor antagonist or at least one beta 3 receptor agonists for the treatment of a disease comprised in a group of diseases consisting of Benign Prostate Hyperplasia (BPH), Bladder Outlet Obstruction (BOO), Lower Urinary Tract Symptoms (LUTS), genitourinary disorders comprising neurogenic bladder syndrome (overactive bladder - OAB, Interstitial Cystits - IC), urinary incontinence (UI) like mixed-, urge, stress- or overflow incontinence (MUI; UUI, SUI, OUI), pelvic pain and other urological disorders.
6. Use of a combination of at least one PDE5 inhibitor and at least one muscarinic receptor antagonist or at least one beta 3 receptor agonists for the treatment of benign and malign disorders of the organs consisting the genitourinary system of female and male, renal diseases like acute or chronic renal failure, immunologically mediated renal disease like renal transplant rejection, lupus nephritis, immune complex renal disease, glomerulaopathies, nephritis, toxic nephropathy, obstructive uropathies and erectile dysfunction.
7. Use of a combination of at least one PDE5 inhibitor and at least one muscarinic receptor antagonist or at least one beta 3 receptor agonists for the preparation of medicaments for the treatment of a disease comprised in a group of diseases consisting of Benign Prostate Hyperplasia (BPH), Bladder Outlet Obstruction (BOO), Lower Urinary Tract Symptoms (LUTS), genitourinary disorders comprising neurogenic bladder syndrome (overactive bladder - OAB, Interstitial Cystits - IC), urinary incontinence (UI) like mixed-, urge, stressor overflow incontinence (MUI; UUI, SUI, OUI), pelvic pain and other urological disorders.
8. Use of a combination of at least one PDE5 inhibitor and at least one muscarinic receptor antagonist or at least one beta 3 receptor agonists for the preparation of medicaments for the treatment of benign and malign disorders of the organs consisting the genitourinary system of female and male, renal diseases like acute or chronic renal failure, immunologically mediated renal disease like renal transplant rejection, lupus nephritis, immune complex renal disease, glomerulaopathies, nephritis, toxic nephropathy, obstructive uropathies and erectile dysfunction.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07021181.8 | 2007-10-30 | ||
| EP07021181 | 2007-10-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2009056232A2 true WO2009056232A2 (en) | 2009-05-07 |
| WO2009056232A3 WO2009056232A3 (en) | 2009-11-12 |
Family
ID=40591546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2008/008765 WO2009056232A2 (en) | 2007-10-30 | 2008-10-16 | Combination of pde5 inhibitors with muscarinic receptor antagonists |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009056232A2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2266568A1 (en) * | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| EP2266567A1 (en) * | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| US8778998B2 (en) | 2009-04-10 | 2014-07-15 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080318982A1 (en) * | 2005-12-20 | 2008-12-25 | Pfizer, Inc. | Pharmaceutical Combination for the Treatment of Luts |
| WO2007113243A2 (en) * | 2006-03-31 | 2007-10-11 | Investigación Y Clínica Andrológicas S.L. | Use of pde 5 inhibitors for the treatment of overactive bladder |
-
2008
- 2008-10-16 WO PCT/EP2008/008765 patent/WO2009056232A2/en active Application Filing
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8778998B2 (en) | 2009-04-10 | 2014-07-15 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
| US9394239B2 (en) | 2009-04-10 | 2016-07-19 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
| US9526711B2 (en) | 2009-04-10 | 2016-12-27 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
| EP2266568A1 (en) * | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| EP2266567A1 (en) * | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009056232A3 (en) | 2009-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2435588C2 (en) | Pde inhibitors and their combinations for treatment of urologic disorders | |
| Eddahibi et al. | Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension | |
| US20240350504A1 (en) | Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations | |
| WO2009056232A2 (en) | Combination of pde5 inhibitors with muscarinic receptor antagonists | |
| WO2007113243A2 (en) | Use of pde 5 inhibitors for the treatment of overactive bladder | |
| Sheng et al. | Down-regulation of EDN1 gene expression by circulating miR-206 is associated with risk of preeclampsia | |
| Gangavarapu et al. | Role of prostate stem cells and treatment strategies in benign prostate hyperplasia | |
| Zhou et al. | Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3 | |
| Gur et al. | Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction: implications for sexual dysfunction | |
| Lee et al. | Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation in healed rat infarcts | |
| CN117042777A (en) | Methods of treating systemic lupus erythematosus using BTK inhibitors | |
| US10987343B2 (en) | Compositions and methods for treating pulmonary diseases | |
| US20190336484A1 (en) | Il-8 inhibitors for use in the treatment of some urological disorders | |
| MX2008004068A (en) | Pde inhibitors and combinations thereof for the treatment of urological disorders | |
| CN116270661A (en) | Mitochondrial Na + /Ca 2+ Application of exchanger blocker in preparation of medicine for improving preeclampsia spiral arterial remodeling failure | |
| Netzel-Arnett et al. | T1684 Protective Role for Matriptase During DSS-Induced Colitis | |
| Managlia et al. | T1683 5-ASA Impacts PI3 Kinase-Mediated â-Catenin Signaling | |
| Rieder et al. | Inflammation-Induced Mucosal Endothelial-to-Mesenchymal Transition (EndoMT): A Novel Mechanism Contributing to the Development of Intestinal Fibrosis | |
| Deba et al. | Role of beta3-adrenoceptors in mouse isolated urinary bladder | |
| Pastuszak et al. | MP47-04 NELL1: A NOVEL GENETIC FACTOR PREDISPOSING TO PEYRONIE’S DISEASE | |
| Kojima et al. | Role of alpha1-adrenoceptor subtype in prostatic growth in a benign prostatic hyperplasia model rat | |
| Hampel et al. | Beta3-Adrenoceptor subtype gene expression in human detrusor tissue associated with bladder outlet obstruction (BOO) and detrusor instability (DI) | |
| Kedia et al. | In vitro functional responses of isolated human prostate tissue to arginase inhibitors | |
| Lin et al. | Estrogen administration attenuates bladder outlet obstruction-induced oxidative stress in female rabbit | |
| Araki et al. | Different role of cold (TRPA1) and cool (TRPM8) receptors in human urogenital organs (bladder and prostate) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08845190 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08845190 Country of ref document: EP Kind code of ref document: A2 |